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Objectives. There are limited clinical data revealing the relationship between mitral annular calciﬁcation (MAC) and systemic
inﬂammation. The goal of the present study was to compare high-sensitivity C-reactive protein (hs-CRP) levels in patients
with and without MAC and investigate the relationship between MAC and hs-CRP. Methods. One hundred patients with MAC
who underwent transthoracic echocardiography (TTE) and 100 age-matched controls without MAC who underwent TTE were
included in our study. Hs-CRP levels were compared between groups. Results. Prevalence of female gender, hypertension, and
coronary artery disease were signiﬁcantly higher in the MAC group than in the control group (64% versus 45%, P = 0.007,
42% versus 28%, P = 0.03 and 37% versus 18%, P = 0.003, resp.). On multivariate analysis, age, gender, and coronary artery
disease were the only independent predictors of MAC. The levels of hs-CRP were higher in the MAC group than in the control
group (2.02 ± 0.35 versus 1.43 ± 0.47mg/dl, P<0.001). This increase in hs-CRP levels in the MAC group persisted in patients
without hypertension, coronary artery disease, and in male patients when compared to the control group. Conclusions. Our study
demonstrated that hs-CRP, which is a sensitive marker of systemic inﬂammation, increased in patients with MAC.
1.Introduction
Mitral annular calciﬁcation (MAC) represents a chronic
and degenerative calciﬁcation of the surrounding ﬁbrous
support of the mitral valve. This process is a common
ﬁnding on echocardiographic examination and progresses
with advanced age [1]. Although the exact mechanism is
not well understood, MAC appears to be associated with
cardiovascular risk factors and clinical atherosclerosis, thus
giving additional evidence for the hypothesis that annular
calciﬁcation is a form of atherosclerosis [2–4].With the
recognition that systemic inﬂammation plays an important
role in the development of atherosclerosis and has an
important etiologic factor of cardiovascular disease [5], it is
possible that this condition may also play a role in the devel-
opment or progression of MAC. There are limited clinical
data supporting the association between MAC and systemic
inﬂammation. High-sensitivity C-reactive protein (hs-CRP)
is a well-known and sensitive marker for prediction of the
degree of systemic inﬂammation [6–10]. The purpose of our
study was to compare the levels of hs-CRP in patients with
MAC and those without MAC.
2.MaterialsandMethods
2.1. Study Population. Participants were recruited from
patients admitted to cardiology department of our hospital.
One hundred consecutive patients in whom a diagnosis of
MAC was made by transthoracic echocardiography (MAC
group) and 100 consecutive age-matched patients without
MAC (control group) were included in our cross-sectional
study. Patients were excluded if they had rheumatic heart
disease, congestive heart failure, cardiomyopathy, prosthetic
valves, renal failure (estimated glomerular ﬁltration ratio2 Mediators of Inﬂammation
(eGFR) below 90mL/min/1.73m2 or serum creatinine
>1.0mg/dL [11]), active inﬂammatory or infective disease,
hematologic disorder, and malignant diseases. The study
was approved by the local ethical committee and written
informed consent was obtained from all patients.
2.2. Echocardiographic Technique. Complete 2-dimensional
transthoracic and doppler colour ﬂow measurements were
performed in all patients with the 4-MHz transducer of a
Phillips ATL 5000 HD (Bothell, WA, USA). The echocardio-
graphic diagnosis of MAC was made by 2-dimensional and
M-mode transthoracic echocardiography. On 2-dimensional
echocardiography, the diagnosis included an intense echo-
producing structure located at the junction of the atrioven-
tricular groove and posterior mitral valve leaﬂet on the
parasternallong-axis,apical4-chamber,orparasternalshort-
axisviews[12].OnM-modeechocardiography,thediagnosis
depended on the appearance of an echocardiographically
dense band throughout systole and diastole, and located
behind the posterior leaﬂet and anterior to the left ventric-
ular posterior wall [13]. Two experienced echocardiologist
unaware of the patients’ clinical data performed all echocar-
diographic evaluations. A patient was chosen for the study
only when the 2 echocardiologists were in agreement about
t h ea b s e n c eo rp r e s e n c eo fM A C .S u b j e c t sw e r ee x c l u d e di f
there was disagreement between two echocardiologists.
2.3. Clinical Data. All patients’ demographic parameters
were recorded and cardiac risk factors were determined:
coronary artery disease (CAD) (>30% luminal diameter nar-
rowing of ≥1 coronary artery by angiography [14], history
of coronary revascularization, an abnormal myocardial per-
fusion scan or dobutamine stress echocardiogram, regional
left ventricular akinesia and/or dyskinesia on echocardio-
gram, or pathologic Q waves on 12-lead electrocardiogram),
systemic hypertension (blood pressure >140/90mm Hg
or ongoing antihypertensive medication), diabetes melli-
tus (fasting serum glucose level >126mg/dL or ongoing
diabetes medication), hypercholesterolemia (fasting serum
total cholesterol level >200mg/dL or ongoing lipid-lowering
therapy), past or present tobacco use.
2.4. High-Sensitivity C-Reactive Protein. A 3mL sample of
peripheral venous blood was obtained from all patients
after echocardiography for the measurement of hs-CRP and
studieddaily.Hs-CRPwasmeasuredusingCobasIutegra700
Analyzer (Roche Diagnostics GmbH, Mannheim, Germany).
2.5. Statistical Analysis. Statistical analyses were performed
with the use of SPSS software, version 17.0 (SPSS). Continu-
ous variables were presented as means ± SD and categorical
v a r i a b l e sa sp e r c e n t a g e s .D i ﬀerences between study groups
in baseline characteristics were assessed with the use of two-
sided Fisher’s exact tests and chi-square tests for categorical
variables and Student’s t tests for continuous variables. Mul-
tivariate binary logistic regression analysis was performed
to determine which clinical variables would independently
predict the development of MAC. MAC entered into model
asadependentvariable.Resultswerepresentedasoddsratios
and 95% conﬁdence intervals. Multiple linear regression
analysis was used to examine the eﬀect of clinical variables
on hs-CRP levels. Hs-CRP level entered into model as a
dependent variable (Table 4). Results were presented as beta
coeﬃcients and 95% conﬁdence intervals. All P values were
two-tailed, and values of less than 0.05 were considered to
indicate statistical signiﬁcance.
3. Results
Baseline characteristics and clinical data of 100 patients
with MAC were compared with baseline characteristics and
clinical data of 100 age-matched patients without MAC and
results were summarized in Table 1. There were more women
in the MAC group than in the control group. Hypertension
and coronary artery disease were more frequent in the MAC
group than in the control group. There were no statistically
signiﬁcant intergroup diﬀerences between MAC and control
groups in diabetes mellitus, hypercholesterolemia, cigarette
smoking, and medication use (Table 1). Multivariate logistic
regression analysis identiﬁed age (odds ratio (OR) 1.09, P =
0.01),femalegender(OR2.06,P = 0.02)andcoronaryartery
disease (OR 0.45, P = 0.02) as the independent variables
signiﬁcantly associated with MAC (Table 2). The adjusted R2
value was 0.45 for this model.
Serum hs-CRP levels in the MAC and control groups
were summarized in Table 3. Signiﬁcant diﬀerences in serum
hs-CRP concentrations were found between patients with
MAC and those without MAC. The levels of hs-CRP in both
female and male patients with MAC were also signiﬁcantly
higher than those without MAC. Patients with CAD in the
MAC group had higher hs-CRP levels than those with CAD
in the control group. There was also statistically signiﬁcant
diﬀerences in hs-CRP levels between patients without CAD
in the MAC and control group. Any statistically signiﬁcant
diﬀerence was not found between hypertensive patients
with and without MAC, though the ﬁrst group had a higher
plasma hs-CRP level. Inversely, patients without hyper-
tension in the MAC group had higher hs-CRP levels than
those patients without hypertension in the control group.
In multiple linear regression analysis, gender (β = 0.26,
P<0.001), hypertension (β = 0.19, P = 0.002), coronary
artery disease (β = 0.22, P<0.001), hypercholesterolemia
(β = 0.18, P = 0.003), and smoking (β = 0.15, P = 0.016)
were all independently associated with the levels of hs-CRP.
The adjusted R2 value was 0.38 for this model.
4. Discussion
Mitral annular calciﬁcation (MAC) is a chronic process
involvingﬁbrosisandcalciﬁcationofthemitralvalvesupport
ring and commonly observed on echocardiograms. Gener-
ally, this process is regarded benign although it is thought
to produce signiﬁcant regurgitation and/or stenosis in rare
circumstances [15]. Consistent with studies describing the
contributions of inﬂammation to atheroma formation [5,
16] and valve calciﬁcation [17], interest in inﬂammatoryMediators of Inﬂammation 3
Table 1: Baseline characteristics of the study population.
Variable MAC Group n = 100 Control Group n = 100 P value
Age, years 65.9 ±4.86 5 .3 ± 4.10 . 1 1
Women/men (%) 64/36 45/55 0.007
Hypertension (%) 42 28 0.03
Coronary artery disease (%) 37 18 0.003
Diabetes mellitus (%) 26 19 0.23
Hypercholesterolemia (%) 33 24 0.15
Cigarette smoking (%) 17 14 0.55
Asetil salisilic acid use (%) 58 48 0.15
Statin use (%) 42 34 0.24
ACEI or ARB use (%) 34 26 0.21
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin-receptor blocker; MAC: mitral annular calciﬁcation.
Table 2:Logisticregressionanalysisformitralannularcalciﬁcation.
Variable Odds ratio 95% CI P value
Age 1.09 1.01–1.17 0.01
Women versus men 2.06 1.11–3.80 0.02
Hypertension 0.62 0.32–1.20 0.16
Coronary artery disease 0.45 0.22–0.90 0.02
Diabetes mellitus 0.79 0.39–1.63 0.53
Hypercholesterolemia 0.63 0.32–1.24 0.18
Cigarette smoking 0.90 0.38–2.01 0.80
CI: conﬁdence interval.
markers has increased because of their potential role as
prognostic markers. Our study aimed to search this issue.
Hs-CRP was used in this study as it is the most frequently
used sensitive marker in systemic inﬂammation. In our
study, mean hs-CRP levels were signiﬁcantly lower in the
control group compared with those in the MAC group
indicatingthatasystemicinﬂammatoryresponsewaspresent
in patients with MAC.
Although a number of hypotheses have been proposed to
elucidate the ectopic deposition of calcium on cardiac struc-
tures [18, 19], the weight of evidence points toward a strong
relationship between the calciﬁcation of the ﬁbrous skeleton
of the base of heart (mitral and aortic annuli) and vascular
atherosclerotic changes. Experimentally induced systemic
arterial atherosclerosis is associated with the deposition of
fatty plaques on the aortic surface of the aortic valve cusps
andtheventricularsurfaceoftheposteriormitralleaﬂet[20].
As the fatty plaques grow, their nutritional needs fail to be
met, and they degenerate into calciﬁc deposits. This ﬁnding
wassupportedbypathologicalstudyshowingthatcollections
of foam cells may be observed on the endothelium of the
epicardial coronary arteries, on the ventricular surface of
the posterior mitral leaﬂet and on the aortic aspects of each
of the aortic valve cusps and already found in adolescence
and the second and third decades of life [21]. These data
suggest that the presence of MAC probably indicates a
systemic atherosclerotic process which involves aortic valve,
mitral valve, coronary arteries, and perhaps other parts of
the arterial systems. Thus, MAC may serve as a marker of
subclinical atherosclerotic disease. In our study, CAD was
more prevalent in the MAC group and this ﬁnding supports
this theory. In addition to the abovementioned mechanisms,
several studies have shown that MAC in elderly women but
not in men can be attributed to ectopic calcium deposits,
related to the severe bone loss caused by postmenopausal
osteoporosis [22–24] and hypovitaminosis D [25].
When the literature is reviewed, MAC is observed more
in patients who have atherosclerotic risk factors such as CAD
and HT [2, 12, 26]. In addition, CAD and HT increase hs-
CRP levels [9, 27]. In our study, patients with and without
CAD in the MAC group were higher hs-CRP levels than
those with and without CAD in the control group. But
interestingly, patients without HT in the MAC group had
higher hs-CRP levels than those without HT in the control
group, which may indicate the presence of inﬂammation
in patients with MAC. Also, compared with hypertensive
patients in the MAC group, nonhypertensive patients in the
same group had slightly, but not signiﬁcantly, higher hs-CRP
levels. This may be due to advanced stage of MAC in this
g r o u po fp a t i e n t s .
It is well known that MAC is more common in females
[28]. In our study, the proportion of female gender in the
MAC group was signiﬁcantly higher than the control group
and this ﬁnding do not diﬀer from most previous clinical
studies[28–30].Thisgenderpredominanceintheprevalence
of MAC seems paradoxical when taking into account the
male predominance in prevalence of atherosclerosis, coro-
nary artery disease, and calciﬁc deposits in the coronary
tree [28]. In our opinion, an explanation of this paradox
may be grounded in possible diﬀerent pathogenesis of MAC
between women and men. In addition, when hs-CRP levels
were compared by gender, males and females with MAC had
higher levels than the ones in the control group who have
thesamegender.Also,ourlogisticregressionanalysisshowed
that gender was an independent risk factor for MAC.
The association of coronary artery disease and hyperten-
sion with MAC, as noted in the present study, is consistent
with the ﬁndings of previous studies [31–33]. In addition,
our logistic regression analysis indicated that older age
and coronary artery disease but not hypertension were
independent risk factors for MAC. On the other hand, there4 Mediators of Inﬂammation
Table 3: Hs-CRP levels in the MAC and control group.
MAC (+) MAC (−) P value
n Hs-CRP (mg/dL) n Hs-CRP (mg/dL)
All patients 100 2.02 ±0.35 100 1.43 ±0.47 <0.001
Females 64 2.05 ±0.35 45 1.64 ±0.39 <0.001
Males 36 1.97 ±0.34 55 1.26 ±0.47 <0.001
CAD (+) 37 2.10 ±0.33 18 1.77 ±0.30 0.001
CAD (−)6 3 1 .97 ±0.35 82 1.36 ±0.47 <0.001
HT (+) 42 1.97 ±0.39 28 1.90 ±0.34 0.47
HT (−)5 82 .06 ±0.32 72 1.25 ±0.39 <0.001
CAD (+): patients with coronary artery disease.
CAD (−): patients without coronary artery disease, Hs-CRP: high-sensitivity C-reactive protein in mg/dL.
HT (+): patients with hypertension.
HT (−): patients without hypertension.
MAC (+): patients with mitral annular calciﬁcation.
MAC (−): patients without mitral annular calciﬁcation.
Table 4: Multiple linear regression analysis with hs-CRP as the de-
pendent variable.
Variable β 95% CI P value
Age 0.64 −0.006–0.021 0.29
Gender (female) 0.26 0.14–0.39 <0.001
Hypertension 0.19 0.07–0.34 0.002
Coronary artery disease 0.22 0.11–0.40 <0.001
Diabetes mellitus 0.05 −0.08–0.21 0.37
Hypercholesterolemia 0.18 0.07–0.34 0.003
Cigarette smoking 0.15 0.04–0.39 0.016
CI: conﬁdence interval.
was no signiﬁcant relationship between MAC and other
traditional risk factors for cardiovascular disease including
hypercholesterolemia, smoking status, and diabetes. Vari-
ous studies have shown inconsistent relationships between
atherosclerotic risk factors and MAC. For example, Nair et
al. looked at the clinical characteristics of patients with MAC
and found that, though there was a signiﬁcant association
between MAC and both diabetes and systemic hypertension,
there was no signiﬁcant relationship between MAC and
serum cholesterol [34]. Adler et al. examined MAC patients
undergoing carotid duplex ultrasound and found that,
though MAC was associated with atherosclerotic disease, it
was not associated with smoking or gender [35]. Allison et
al. found that individuals with MAC were more likely to be
older and have a history of hypertension and smoking, but
diabetes and hyperlipidemia were not associated with MAC
[36]. These diﬀerences with our study might be explained in
part by patient population and/or statistical power.
Findings of our study are partly consistent with the
results of the Cardiovascular Health Study which found an
association between MAC and hs-CRP levels [37]. However,
in the Cardiovascular Health Study, prevalent CAD and all
cardiovascular risk factors including hypertension, diabetes,
smoking, and hypercholesterolemia were signiﬁcantly higher
in the MAC group. All these factors may have contributed to
increase hs-CRP level. In that study, the relationship between
MAC and hs-CRP has not been examined in detail even if
it revealed the relationship between them. Our study aims
to demonstrate the contributions of these risk factors to
the relationship between MAC and hs-CRP. High levels of
hs-CRP in our MAC group show an association between
MAC and hs-CRP. However, our study is not explanatory
enough in terms of cause and eﬀect relationship. This study
does not clarify whether MAC itself increases hs-CRP or
MAC occurs because CRP increases or there are other
factors aﬀecting these two situations. However, our logistic
regression analysis identiﬁed age, female gender, and CAD
as independent risk factors for MAC, whereas HT was not,
which may be explained by the concomitant presence of
other cardiovascular risk factors. In addition, our multiple
regression analysis showed that female gender, hypertension,
CAD, hypercholesterolemia, and smoking showed indepen-
dent correlations with plasma hs-CRP.
5. Study Limitations
This study has several limitations. One of which was the
cross-sectional design. Although cross-sectional studies can
measure association, they are not strong enough to prove
causality. It would have been ideal to have obtained serial
echocardiograms and hs-CRP levels in our study patients to
prove causality. Because our sample size was relatively small,
this study may not be representative of the general popula-
tionorpopulationsfromcommunity-based.Inaddition,our
studypopulation consistedofpredominantly elderlypatients
who might have higher hs-CRP levels than younger patients
because of aging or nonspeciﬁc etiologies. Lastly, we did
not assess the severity of MAC. Further study is needed to
examine the relationship between systemic biomarkers of
inﬂammation and valvular and/or annular calciﬁcation.
6. Conclusion
Our study demonstrated that hs-CRP, which is a sensitive
marker of systemic inﬂammation, increased in patients with
MAC. This increase in hs-CRP levels in the MAC groupMediators of Inﬂammation 5
persisted in patients without hypertension, coronary artery
disease, and in male patients when compared to the control
group. There is a need for studies which are designed to
present the signiﬁcance of the relationship of MAC with
inﬂammatory process and its clinical importance.
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